TopoGEN is partnering with a prominent analytical chemist based in South Africa on the development of innovative anti-topo I and II targeting drugs based on synthetic structures containing gold. Evidence demonstrates the combination of poisoning and catalytic inhibition of the DNA topoisomerase pathways. Initial screens performed by NCI demonstrated efficacy in cancer and subsequent confirmation by TopoGEN is showing topoisomerase targeting. Further studies are pending SBIR phase I review and the acquisition of patents filed in the U.S. and abroad. Check back for further details.